Aurora Cannabis (TSX:ACB): 5 Must-Know Takeaways From Latest Earnings Guidance

Here’s what you need to know in Aurora Cannabis Inc.’s (TSX:ACB)(NYSE:ACB) latest earnings guidance for the June quarter.

| More on:
Female scientist in a hemp field checking plants and flowers, alternative herbal medicine concept

Image source: Getty Images

Aurora Cannabis (TSX:ACB)(NYSE:ACB) is developing a culture of unparalleled transparency and market openness that is very welcome, commendable, and exemplary for the nascent cannabis industry.

Management’s latest (and second such) earnings guidance for the recently closed June quarter and fiscal year 2019 gives testimony to that, and the numbers are just beautiful.

Here’s what you need to know about the company’s upcoming earnings report in September and why you should care.

Strong revenue growth

Net revenue for the last quarter is expected in the range of $100-107 million, representing a strong 54-64% sequential growth from a previous quarter and a massive 424-460% increase from comparable quarterly sales last yaer.

Most noteworthy, the majority of this quarterly revenue, at $90-95 million, is pure cannabis net revenue from internal operations, unlike at Aphria, where about 78% of net sales were lower-margin distribution revenues from externally purchased products in the recently reported quarter.

Annual net revenues are expected to be within the $246-256 million range.

Company exceeded production targets

Prior guidance was for the company to produce and have available for sale about 25,000 kilograms of cannabis during the recently closed quarter. Management expects to report a better number that is close to the upper end of the 25,000-30,000 kilogram range as inventory available for sale during the quarter. This would be much better than the earlier guidance.

The company has potentially benefited significantly from the recent full licensing at flagship Aurora Sky facility.

Growth in all revenue-generating segments

While other leading industry players like Canopy Growth have seen medical cannabis sales trending lower before and after recreational legalization, Aurora is still growing this segment, and it expects to report positive growth all segments, including exports and adult use sales.

The company commenced higher-margin oil sales to Germany pharmacies in March.

Margin expansions loading

Aurora may report sequentially better quarterly adjusted gross margins, lower cash costs per gram produced, and higher kilograms of cannabis sold during the quarter.

If average selling prices didn’t soften during the quarter, and if operating costs were contained, operating margins could improve too, and that would be wonderful news, as the company targets positive adjusted EBITDA in the near term. This brings us to the last matter.

A lukewarm comment on adjusted EBITDA

An earlier management guidance in May was that the company was “on track to deliver positive EBITDA beginning in fiscal Q4 2019,” and that statement was made midway into the quarter (the fiscal Q4 2019), but the latest guidance is that “the company continues to track toward positive adjusted EBITDA, and in particular adjusted EBITDA from cannabis operations.”

Could it be possible that the positive adjusted EBITDA target was missed for the recently closed quarter, or else the company intends to surprise the market come September?

Investor takeaway

Aurora stock traded over 6% higher after delivering an earnings guidance, and the numbers promise to be exciting in September, but I have a keen interest in the adjusted EBITDA figure, specifically from cannabis operations. And I still expect recreational sales to take the lead.

The stock could be on track to a strong price recovery if all boxes tick in the next earnings release.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Brian Paradza has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Are Cannabis Stocks a Good Buy in March 2023?

Cannabis stocks like Canopy Growth Corp (TSX:WEED) are still being talked about, but are they worth buying?

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Down 26% in a Month, Is Canopy a Buy Today?

Canopy Growth Corp (TSX:WEED) is down 26% in a month. Is it time to start bottom fishing?

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

What’s Next for Aurora Cannabis Stock?

Aurora Cannabis stock is down 99% from all-time highs. Is ACB stock a buy, sell, or hold in March 2023?

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Canopy Growth Stock: Undervalued Gem or Falling Knife?

Canopy Growth remains a high-risk bet, despite falling 95% from all-time highs. Let's see why you need to avoid WEED…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

3 Things to Know About Canopy Growth Stock After Earnings

A new focus on profitability and sustainability might stop the cash burn at Canopy Growth, so the stock can see…

Read more »

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »